Viatris Recalls Xanax XR Due to Dissolution Test Failure

Viatris has initiated a voluntary recall of one batch of its extended-release anti-anxiety medication, Xanax XR, in the United States. The recall was prompted by the batch's failure to meet dissolution specifications, which are critical for determining the drug's bioavailability and efficacy. Specifically, the recalled lot, consisting of 60 tablets of 3 mg Xanax XR, was manufactured in Ireland and distributed from Viatris's facility in Morgantown, West Virginia. The recall was classified as Class II by the FDA, indicating that the products may have short-term or medically reversible negative health effects.

The One Batch That Might Not Be Working the Way It ShouldBioSpace

Xanax XR, which contains the active ingredient alprazolam, was approved by the FDA in 2003, shortly before Pfizer acquired Pharmacia for $60 billion. The extended-release formulation allows for once-daily dosing, a significant convenience compared to the immediate-release version that required multiple doses throughout the day. This innovation helped Pfizer grow Xanax sales to $350 million by 2008. However, as generic versions entered the market, including those from Actavis and Aurobindo Pharma, sales began to decline, with Viatris reporting $139.9 million in Xanax sales last year, down from $154.8 million in 2023.

BioSpaceThe One Batch That Might Not Be Working the Way It Should

The recall raises concerns about the manufacturing consistency of Xanax XR, as this is not the first instance of dissolution-related issues. Viatris previously recalled 110 bottles of Xanax XR four years ago for similar reasons, and Pfizer had recalled 36,000 bottles of immediate-release Xanax in 2012 due to dissolution test failures. While Viatris has clarified that the recall affects only one lot of the branded product, the incident highlights potential vulnerabilities in the production process of a medication that many patients rely on for managing anxiety.

The One Batch That Might Not Be Working the Way It ShouldBioSpace

The recall has sparked anxiety among patients who depend on Xanax XR for stability in their daily lives. The public's sensitivity to news about this medication is evident, as reports of the recall quickly spread through major media outlets, including Forbes and NBC Chicago. While there have been no reported illnesses or injuries related to the recalled lot, the situation may contribute to a decline in trust in the medication. Patients experiencing decreased efficacy during the affected period may attribute their symptoms to fluctuations in their condition, rather than recognizing a potential issue with the medication itself.

The One Batch That Might Not Be Working the Way It Should

Viatris has emphasized that the majority of patients in the U.S. are prescribed generic alprazolam, which is not affected by this recall. A representative stated, "The recall only affects one lot of one strength of the branded product," aiming to reassure patients about the broader availability of effective treatments.

The One Batch That Might Not Be Working the Way It Should

• “A representative emphasized that the great majority of patients in the US are prescribed generic alprazolam, which is unaffected by the recall, and confirmed that the recall only affects one lot of one strength of the branded product.” — Viatris Representative

The One Batch That Might Not Be Working the Way It Should

The recall of Xanax XR by Viatris underscores the importance of rigorous quality control in pharmaceutical manufacturing. While the immediate health risks appear limited, the broader implications for patient trust and medication efficacy warrant careful attention from both the company and healthcare providers.

The One Batch That Might Not Be Working the Way It Should